Twist Bioscience Corporation · NASDAQ:TWST

Twist Bioscience — Q4 2026 Earnings Presentation

26 slides from Twist Bioscience's earnings presentation, Nov 12, 2026

  1. Slide 1: Fiscal 2026 Q4 and Full Year Financial Results

    Fiscal 2026 Q4 and Full Year Financial Results NOVEMBER 2026

  2. Slide 2: Legal Disclaimer

    Legal Disclaimer This presentation contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflect the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Secur

  3. Slide 3: 15 Consecutive Quarters of Sequential Revenue Growth

    15 Consecutive Quarters of Sequential Revenue Growth Revenue $ in Millions FY23-FY26 Total Revenue CAGR: +23% NGS Applications NGS Applications +24% $126.6 DNA Synthesis & Protein Solutions DNA Synthesis & Protein Solutions +22% $118.4 $110.7 $103.7 $99.0 $96.1 $92.8 $88.7 $84.7 $81.5 $75.3 $71.5 $6

  4. Slide 4: Robust FY2026 and 4QFY26 Financial Momentum

    Robust FY2026 and 4QFY26 Financial Momentum $2.2M $459.4M 52.4% 4QFY26 FY2026 Revenue FY2026 Gross Margin Adj. EBITDA** ~$30M (+7%) above GM% +170bps YoY Achieved 4QFY26 initial FY26 guidance* vs. FY2025 breakeven target Cash, Cash Equivalents and Short-term Investments as of 09/30/26 $582 million f

  5. Slide 5: Proprietary Platform and Execution Support Future Growth

    Proprietary Platform and Execution Support Future Growth New Product Introduction Frictionless e-Commerce (NPI) Machine Platform Structural Cost, Scale & Disciplined Reinvestment to Speed Advantages Across Expanded Portfolio fuel future growth Diverse Applications Capacity Expansion & Commercial Exe

  6. Slide 6: AI-enabled Discovery: A Durable, Repeatable Revenue Stream

    AI-enabled Discovery: A Durable, Repeatable Revenue Stream Preclinical 1 Design 2 Build 3 Build 4 Test 5 Test development & AI-Generated DNA Synthesis Protein Expression Characterization Lead Candidates animal studies Sequences Millions of candidate DNA High-throughput synthesis of Expression of the

  7. Slide 7: Nucleic Acid Therapeutics: Future Growth Frontier

    Nucleic Acid Therapeutics: Future Growth Frontier Unique, high-quality DNA/RNA synthesis requirements leverage existing platform advantages Manufacturing bottlenecks will require speed and scale for future market adoption Currently offering research-grade mRNA to select early access customers; plans

  8. Slide 8: 4Q FY2026 NGS Applications Growth Accelerates to 24%

    4Q FY2026 NGS Applications Growth Accelerates to 24% • FY2026 Revenue cadence consistent with expectations • Growth led by diagnostic customers as commercial volumes scale • Molecular Residual Disease (MRD) added ~1pt-2pts of revenue growth in FY2026 • MRD Express launch and expanded writer capacity

  9. Slide 9: Disciplined Capacity Investments Guided by Customer Demand

    Disciplined Capacity Investments Guided by Customer Demand ~$425M of net proceeds Acceleration of capex purchases • Antibody characterization breadth • AI drug discovery $582M • • MRD Other growth opportunities Cash, Cash Equivalents & Short-Term Flexibility to pursue near-term, high ROI Investments

  10. Slide 10: Disciplined Capacity Investments Guided by Customer Demand

    Disciplined Capacity Investments Guided by Customer Demand • Investment objective: handle more programs at rigorous speed and scale • Further capacity investments planned/ongoing to support larger, more complex programs • Protein characterization capacity to increase significantly in FY2027 • 10 wri

  11. Slide 11: MRD Express Unlocks Tumor Informed Applications

    MRD Express* Unlocks Tumor Informed Applications Competitive Approaches: Speed + Sensitivity + Scale Chemo window opens MRD result available Surgery Blood draw for MRD Optimal window closes Custom panels up to 10,000 probes designed around individual tumor variants Wk1 Wk2 Wk3 Wk4 Wk5 Wk6 Wk7 Wk8 Wk

  12. Slide 12: 4Q FY2026: Strong Finish to Very Strong Fiscal Year

    4Q FY2026: Strong Finish to Very Strong Fiscal Year $126.6M 53.1% $2.2M Revenue Gross Margin Adj. EBITDA* Beat Guidance of ~$123M-$124M ~180 basis points of Achieved 4Q FY2026 growth YoY breakeven target Revenue Growth of 28% YoY Cash, Cash Equivalents and Short-term Investments as of 09/30/26 $582

  13. Slide 13: DNA Synthesis & Protein Solutions

    DNA Synthesis & Protein Solutions 4Q FY26 FY2026 Products • $61.0 million in revenue, • $221.9 million in revenue, growth of 33% YoY growth of 32% YoY • Clonal genes • Physically shipped ~401,000 genes, • Physically shipped ~1.3M genes, • Express genes +49% YoY +43% YoY • Gene fragments* • Internal

  14. Slide 14: NGS Applications

    NGS Applications 4Q FY26 FY2026 Products • $65.7 million in revenue, • $237.5 million in revenue, growth of 24% YoY growth of 14% YoY • Fixed panels • Increased purchasing from • Served 704 customers, with 190 • Custom panels diagnostics customers customers adopting, as of • Alliance panels Septembe

  15. Slide 15: 4Q FY2026 and FY2026 Industry Revenue Reporting

    4Q FY2026 and FY2026 Industry Revenue Reporting 4Q FY2026 Industry Reporting (% change vs. 4Q FY2025)* +44% +23% +21% +12% +18% Academic and Industry and Global supply Therapeutics Diagnostics Government applied partners $43.9M $45.2M $16.1M $6.6M $15.0M Discovery research, Tools for NGS assays, Res

  16. Slide 16: Revenue by Geography

    Revenue by Geography $ in Millions Americas EMEA APAC Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025 FY2026 PROPRIETARY | TWIST BIOSCIENCE | 16

  17. Slide 17: Key Metrics: Revenue, Gross Margin, Adj EBITDA

    Key Metrics: Revenue, Gross Margin, Adj EBITDA $550–$560 Quarterly Revenue $ in Millions Annual Revenue $459.4 $126.6 $ in Millions $376.6 52.5-53% 53.1% 52% $313.0 51% GM GM GM GM $245.1 $203.6 $132.2 43% $90.1 41% GM 39% GM 37% 32% GM GM GM FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 F

  18. Slide 18: Adjusted EBITDA Breakeven Target Met in 4Q FY2026

    Adjusted EBITDA Breakeven Target Met in 4Q FY2026 $ in Millions $126.6 $118.4 $110.7 $103.7 $96.1 $99.0 $88.7 $92.8 $81.5 $84.7 $71.5 $75.3 53.4% 52.0% 52.8% 53.1% 51.3% 51.6% 48.3% 49.6% 45.1% 43.3% 40.5% 41.0% FY24Q1 FY24Q2 FY24Q3 FY24Q4 FY25Q1 FY25Q2 FY25Q3 FY25Q4 FY26Q1 FY26Q2 FY26Q3 FY26Q4 Reve

  19. Slide 19: Balance Sheet and Capital Allocation

    Balance Sheet and Capital Allocation $582M Flexibility to Invest in $150M Capacity & Capabilities Cash, Cash Equivalents and Ahead of Anticipated Planned CapEx from Short-term Investments at Demand FY2027 through FY2028 FY2026-end • ~$425M aggregate net • FY2026 characterization and • Investment foc

  20. Slide 20: FY2027 Guidance

    FY2027 Guidance* 1Q FY2027 FY2027 FY2027 Revenue Revenue Gross Margin $130M to $132M $550M to $560M ~52.5% to 53% Growth of 26% YoY at midpoint Growth of 21% YoY at midpoint Positive Full-year Adjusted EBITDA ~$75M of Capital Expenditures FY2027** FY2027*** * Guidance provided as of November 12, 202

  21. Slide 21: Building on Broad Momentum to Deliver Durable Growth

    Building on Broad Momentum to Deliver Durable Growth Strong Growth Assumed $100M of AI Guided to $550M to Revenue Growth Trajectory Drug Discovery in $560M in FY2027 FY2027 Guidance 28% YoY growth and 15th 1QFY27 guide of $130M to quarter of consecutive growth Growth of approximately 21% $132M, grow

  22. Slide 22: Writing the Future

    Writing the Future

  23. Slide 23: Adjusted EBITDA Reconciliation

    Adjusted EBITDA Reconciliation (In Thousands) FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY2025 FY2026 GAAP Net Income (Loss) ($139,931) ($152,098) ($217,863) ($204,618) ($208,726) ($77,670) ($130,202) Add (Deduct) Adjustments: Interest income (1,499) (435) (3,062) (14,365) (15,344) (11,364) (8,803) In

  24. Slide 24: Adjusted R&D and SG&A Expenses Reconciliation

    Adjusted R&D and SG&A Expenses Reconciliation (In Millions) FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 R&D Expenses — GAAP $43.0 $69.1 $120.3 $106.9 $90.9 $80.3 $71.8 Adjusted to exclude: Depreciation and Amortization 3.0 3.2 3.5 4.0 3.0 1.3 1.1 Stock-based Compensation Expense 3.3 10.2

  25. Slide 25: Adjusted EBITDA Reconciliation

    Adjusted EBITDA Reconciliation (In Thousands) Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026 GAAP Net Income (Loss) ($43,008) ($45,492) ($85,571) ($34,655) ($31,594) ($39,328) $20,390 ($27,138) ($30,507) ($44,021) ($35,051) ($20,623) Add (Deduct) Adju

  26. Slide 26: Adjusted R&D and SG&A Expenses Reconciliation

    Adjusted R&D and SG&A Expenses Reconciliation (In Millions) Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026 R&D Expenses — GAAP $23.1 $24.1 $22.5 $21.1 $21.3 $23.9 $18.0 $17.0 $17.1 $19.7 $18.0 $17.0 Adjusted to exclude: Depreciation and 0.9 0.9 0.9 0.

Twist Bioscience — Q4 2026 Earnings Presentation on 6ix